Actuellement, il n'existe pas de méthodes connues pour prévenir le neuroblastome.
PréventionNeuroblastomeFacteurs de risque
#2
Y a-t-il des facteurs de risque identifiés ?
Des facteurs génétiques et environnementaux peuvent augmenter le risque de neuroblastome.
Facteurs de risqueGénétiqueEnvironnement
#3
Les antécédents familiaux influencent-ils le risque ?
Oui, un antécédent familial de neuroblastome peut augmenter le risque chez les enfants.
Antécédents familiauxNeuroblastomeRisque
#4
Les infections virales sont-elles un facteur de risque ?
Certaines infections virales ont été étudiées, mais leur lien avec le neuroblastome reste incertain.
Infections viralesNeuroblastomeFacteurs de risque
#5
L'exposition à des produits chimiques augmente-t-elle le risque ?
Des études suggèrent que l'exposition à certains produits chimiques pourrait être un facteur de risque.
Produits chimiquesExpositionNeuroblastome
Traitements
5
#1
Quels sont les traitements standards pour le neuroblastome ?
Les traitements incluent la chirurgie, la chimiothérapie, la radiothérapie et l'immunothérapie.
ChirurgieChimiothérapieRadiothérapie
#2
La chirurgie est-elle toujours nécessaire ?
Pas toujours, cela dépend de la taille et de l'emplacement de la tumeur ainsi que de son stade.
ChirurgieStade du cancerNeuroblastome
#3
Qu'est-ce que l'immunothérapie pour le neuroblastome ?
L'immunothérapie utilise le système immunitaire pour cibler et détruire les cellules cancéreuses.
ImmunothérapieNeuroblastomeSystème immunitaire
#4
Quels effets secondaires peuvent survenir avec la chimiothérapie ?
Les effets secondaires incluent la fatigue, les nausées, la perte de cheveux et les infections.
ChimiothérapieEffets secondairesInfections
#5
Le traitement du neuroblastome varie-t-il selon le stade ?
Oui, le traitement est adapté en fonction du stade de la maladie et de la réponse au traitement.
Stade du cancerTraitementNeuroblastome
Complications
5
#1
Quelles complications peuvent survenir avec le neuroblastome ?
Les complications incluent la propagation de la maladie, des infections et des effets secondaires des traitements.
ComplicationsPropagationInfections
#2
Le neuroblastome peut-il affecter d'autres organes ?
Oui, il peut se propager aux os, au foie et à d'autres organes, entraînant des complications graves.
PropagationOrganesNeuroblastome
#3
Comment les traitements peuvent-ils causer des complications ?
Les traitements comme la chimiothérapie peuvent affaiblir le système immunitaire et causer des infections.
ChimiothérapieComplicationsSystème immunitaire
#4
Y a-t-il des complications à long terme ?
Oui, certains patients peuvent développer des complications à long terme, comme des problèmes de croissance.
Complications à long termeCroissanceNeuroblastome
#5
Les complications psychologiques sont-elles possibles ?
Oui, les enfants peuvent éprouver des complications psychologiques, comme l'anxiété et la dépression.
Complications psychologiquesAnxiétéDépression
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Neuroblastome : Questions médicales les plus fréquentes",
"headline": "Neuroblastome : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Neuroblastome : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-03-31",
"dateModified": "2024-12-26",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Neuroblastome"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Tumeurs neuroectodermiques primitives périphériques",
"url": "https://recherchemedicale.com/mesh/D018241",
"about": {
"@type": "MedicalCondition",
"name": "Tumeurs neuroectodermiques primitives périphériques",
"code": {
"@type": "MedicalCode",
"code": "D018241",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.580.625.600.590.650"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Ganglioneuroblastome",
"alternateName": "Ganglioneuroblastoma",
"url": "https://recherchemedicale.com/mesh/D018305",
"about": {
"@type": "MedicalCondition",
"name": "Ganglioneuroblastome",
"code": {
"@type": "MedicalCode",
"code": "D018305",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.580.625.600.590.650.550.300"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Neuroblastome",
"alternateName": "Neuroblastoma",
"code": {
"@type": "MedicalCode",
"code": "D009447",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Anna Rita Gigliotti",
"url": "https://recherchemedicale.com/author/Anna%20Rita%20Gigliotti",
"affiliation": {
"@type": "Organization",
"name": "Epidemiology and Biostatistics Unit, IRCCS Istituto Giannina Gaslini, Genova, Italy."
}
},
{
"@type": "Person",
"name": "Giovanni Erminio",
"url": "https://recherchemedicale.com/author/Giovanni%20Erminio",
"affiliation": {
"@type": "Organization",
"name": "Epidemiology and Biostatistics Unit, IRCCS Istituto Giannina Gaslini, Genova, Italy."
}
},
{
"@type": "Person",
"name": "Bruno De Bernardi",
"url": "https://recherchemedicale.com/author/Bruno%20De%20Bernardi",
"affiliation": {
"@type": "Organization",
"name": "Oncology Unit, IRCCS Istituto Giannina Gaslini, Genova, Italy."
}
},
{
"@type": "Person",
"name": "Rui Dong",
"url": "https://recherchemedicale.com/author/Rui%20Dong",
"affiliation": {
"@type": "Organization",
"name": "Department of Pediatric Surgery, Children's Hospital of Fudan University, Shanghai, China."
}
},
{
"@type": "Person",
"name": "Giuseppe Martucciello",
"url": "https://recherchemedicale.com/author/Giuseppe%20Martucciello",
"affiliation": {
"@type": "Organization",
"name": "Pediatric Surgery Unit, IRCCS Istituto Giannina Gaslini, Largo Gaslini 5, 16147, Genoa, Italy."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Classification of Local Recurrence After Nipple-Sparing Mastectomy Based on Location: The Features of Nipple-Areolar Recurrence Differ from Those of Other Local Recurrences.",
"datePublished": "2022-11-13",
"url": "https://recherchemedicale.com/article/36371582",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1245/s10434-022-12760-1"
}
},
{
"@type": "ScholarlyArticle",
"name": "Feasibility of local therapy for recurrent pancreatic cancer.",
"datePublished": "2022-05-24",
"url": "https://recherchemedicale.com/article/35641368",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.pan.2022.05.004"
}
},
{
"@type": "ScholarlyArticle",
"name": "Ultrasound Assessment of Skin Tumors Local Recurrence.",
"datePublished": "2023-05-17",
"url": "https://recherchemedicale.com/article/37195073",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/jum.16255"
}
},
{
"@type": "ScholarlyArticle",
"name": "Pathological determinants of outcome following resection of locally advanced or locally recurrent rectal cancer.",
"datePublished": "2023-06-26",
"url": "https://recherchemedicale.com/article/37442715",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ejso.2023.06.023"
}
},
{
"@type": "ScholarlyArticle",
"name": "Intraparenchymal metastases as a cause for local recurrence of pancreatic cancer.",
"datePublished": "2022-11-21",
"url": "https://recherchemedicale.com/article/36371607",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/his.14839"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Recherchemedicale.com",
"item": "https://recherchemedicale.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Tumeurs",
"item": "https://recherchemedicale.com/mesh/D009369"
},
{
"@type": "ListItem",
"position": 3,
"name": "Tumeurs par type histologique",
"item": "https://recherchemedicale.com/mesh/D009370"
},
{
"@type": "ListItem",
"position": 4,
"name": "Tumeurs du tissu nerveux",
"item": "https://recherchemedicale.com/mesh/D009380"
},
{
"@type": "ListItem",
"position": 5,
"name": "Tumeurs neuroectodermiques",
"item": "https://recherchemedicale.com/mesh/D017599"
},
{
"@type": "ListItem",
"position": 6,
"name": "Tumeurs neuroépitheliales",
"item": "https://recherchemedicale.com/mesh/D018302"
},
{
"@type": "ListItem",
"position": 7,
"name": "Tumeurs neuroectodermiques primitives",
"item": "https://recherchemedicale.com/mesh/D018242"
},
{
"@type": "ListItem",
"position": 8,
"name": "Tumeurs neuroectodermiques primitives périphériques",
"item": "https://recherchemedicale.com/mesh/D018241"
},
{
"@type": "ListItem",
"position": 9,
"name": "Neuroblastome",
"item": "https://recherchemedicale.com/mesh/D009447"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Neuroblastome - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Neuroblastome",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-01-22",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Neuroblastome",
"description": "Comment diagnostique-t-on un neuroblastome ?\nQuels tests d'imagerie sont utilisés ?\nQuels marqueurs sanguins sont associés au neuroblastome ?\nLe neuroblastome peut-il être confondu avec d'autres maladies ?\nQuel rôle joue la biopsie dans le diagnostic ?",
"url": "https://recherchemedicale.com/mesh/D009447?mesh_terms=Neoplasm+Recurrence,+Local#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Neuroblastome",
"description": "Quels sont les symptômes courants du neuroblastome ?\nLe neuroblastome peut-il causer des symptômes neurologiques ?\nComment se manifeste le neuroblastome chez les nourrissons ?\nY a-t-il des symptômes spécifiques selon l'âge ?\nLe neuroblastome peut-il provoquer des symptômes respiratoires ?",
"url": "https://recherchemedicale.com/mesh/D009447?mesh_terms=Neoplasm+Recurrence,+Local#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Neuroblastome",
"description": "Peut-on prévenir le neuroblastome ?\nY a-t-il des facteurs de risque identifiés ?\nLes antécédents familiaux influencent-ils le risque ?\nLes infections virales sont-elles un facteur de risque ?\nL'exposition à des produits chimiques augmente-t-elle le risque ?",
"url": "https://recherchemedicale.com/mesh/D009447?mesh_terms=Neoplasm+Recurrence,+Local#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Neuroblastome",
"description": "Quels sont les traitements standards pour le neuroblastome ?\nLa chirurgie est-elle toujours nécessaire ?\nQu'est-ce que l'immunothérapie pour le neuroblastome ?\nQuels effets secondaires peuvent survenir avec la chimiothérapie ?\nLe traitement du neuroblastome varie-t-il selon le stade ?",
"url": "https://recherchemedicale.com/mesh/D009447?mesh_terms=Neoplasm+Recurrence,+Local#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Neuroblastome",
"description": "Quelles complications peuvent survenir avec le neuroblastome ?\nLe neuroblastome peut-il affecter d'autres organes ?\nComment les traitements peuvent-ils causer des complications ?\nY a-t-il des complications à long terme ?\nLes complications psychologiques sont-elles possibles ?",
"url": "https://recherchemedicale.com/mesh/D009447?mesh_terms=Neoplasm+Recurrence,+Local#section-complications"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostique-t-on un neuroblastome ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des examens d'imagerie, des biopsies et des analyses sanguines."
}
},
{
"@type": "Question",
"name": "Quels tests d'imagerie sont utilisés ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les échographies, IRM et TEP-scan sont couramment utilisés pour visualiser la tumeur."
}
},
{
"@type": "Question",
"name": "Quels marqueurs sanguins sont associés au neuroblastome ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les niveaux de la dopamine et de la vanillylmandélique acid (VMA) peuvent être élevés."
}
},
{
"@type": "Question",
"name": "Le neuroblastome peut-il être confondu avec d'autres maladies ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il peut être confondu avec d'autres tumeurs pédiatriques ou maladies neurologiques."
}
},
{
"@type": "Question",
"name": "Quel rôle joue la biopsie dans le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "La biopsie permet de confirmer la présence de cellules tumorales et de déterminer le type de tumeur."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants du neuroblastome ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des douleurs abdominales, des masses abdominales et des ecchymoses."
}
},
{
"@type": "Question",
"name": "Le neuroblastome peut-il causer des symptômes neurologiques ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il peut entraîner des symptômes neurologiques comme des troubles de la marche ou des convulsions."
}
},
{
"@type": "Question",
"name": "Comment se manifeste le neuroblastome chez les nourrissons ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Chez les nourrissons, il peut se manifester par une masse abdominale et des troubles de l'alimentation."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques selon l'âge ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent varier selon l'âge, avec des manifestations plus sévères chez les jeunes enfants."
}
},
{
"@type": "Question",
"name": "Le neuroblastome peut-il provoquer des symptômes respiratoires ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, si la tumeur se développe dans la région thoracique, elle peut causer des difficultés respiratoires."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir le neuroblastome ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de méthodes connues pour prévenir le neuroblastome."
}
},
{
"@type": "Question",
"name": "Y a-t-il des facteurs de risque identifiés ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des facteurs génétiques et environnementaux peuvent augmenter le risque de neuroblastome."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux influencent-ils le risque ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un antécédent familial de neuroblastome peut augmenter le risque chez les enfants."
}
},
{
"@type": "Question",
"name": "Les infections virales sont-elles un facteur de risque ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections virales ont été étudiées, mais leur lien avec le neuroblastome reste incertain."
}
},
{
"@type": "Question",
"name": "L'exposition à des produits chimiques augmente-t-elle le risque ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études suggèrent que l'exposition à certains produits chimiques pourrait être un facteur de risque."
}
},
{
"@type": "Question",
"name": "Quels sont les traitements standards pour le neuroblastome ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent la chirurgie, la chimiothérapie, la radiothérapie et l'immunothérapie."
}
},
{
"@type": "Question",
"name": "La chirurgie est-elle toujours nécessaire ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Pas toujours, cela dépend de la taille et de l'emplacement de la tumeur ainsi que de son stade."
}
},
{
"@type": "Question",
"name": "Qu'est-ce que l'immunothérapie pour le neuroblastome ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'immunothérapie utilise le système immunitaire pour cibler et détruire les cellules cancéreuses."
}
},
{
"@type": "Question",
"name": "Quels effets secondaires peuvent survenir avec la chimiothérapie ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires incluent la fatigue, les nausées, la perte de cheveux et les infections."
}
},
{
"@type": "Question",
"name": "Le traitement du neuroblastome varie-t-il selon le stade ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le traitement est adapté en fonction du stade de la maladie et de la réponse au traitement."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec le neuroblastome ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent la propagation de la maladie, des infections et des effets secondaires des traitements."
}
},
{
"@type": "Question",
"name": "Le neuroblastome peut-il affecter d'autres organes ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il peut se propager aux os, au foie et à d'autres organes, entraînant des complications graves."
}
},
{
"@type": "Question",
"name": "Comment les traitements peuvent-ils causer des complications ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements comme la chimiothérapie peuvent affaiblir le système immunitaire et causer des infections."
}
},
{
"@type": "Question",
"name": "Y a-t-il des complications à long terme ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains patients peuvent développer des complications à long terme, comme des problèmes de croissance."
}
},
{
"@type": "Question",
"name": "Les complications psychologiques sont-elles possibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les enfants peuvent éprouver des complications psychologiques, comme l'anxiété et la dépression."
}
}
]
}
]
}
Department of Pediatrics, Division of Oncology, Children's Hospital of Philadelphia and the Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Department of Paediatrics, Division of Paediatric Hematology and Oncology, University of California San Francisco, San Francisco, CA, USA. kate.matthay@ucsf.edu.
Little information is available about the clinical and pathologic characteristics of local recurrence (LR) after nipple-sparing mastectomy according to the locations of LR....
This study classified 99 patients into the following two groups according to the location of LR after nipple-sparing mastectomy: nipple-areolar recurrence (NAR) group and other locations of LR (oLR) g...
For about half of the patients (44.4 %) with NAR, the primary cancer was estrogen receptor (ER)-negative and human epidermal growth factor receptor 2 (HER2)-positive. Conversely, in most of the patien...
This multi-institutional retrospective study demonstrated that the features of NAR, such as the characteristics of the primary and recurrent tumors and the prognostic factors after LR resection, were ...
Despite advances in perioperative management, recurrence after curative pancreatectomy is a critical issue in the treatment of pancreatic ductal adenocarcinoma (PDAC). The significance of local therap...
We reviewed the medical records of patients with PDAC who underwent curative resection at our institution between January 2009 and December 2019. We examined the patterns of relapse and assessed the c...
A total of 246 patients with PDAC who underwent R0 or R1 resection were included in this study. The 3-year overall survival (OS) rate was 39.8%, and the 1-year recurrence-free survival rate was 51.2% ...
Our results suggest that a multimodal approach may improve the clinical outcomes of patients with recurrent PDAC....
Skin cancer may recur at or around the surgical site despite wide excisions. Prompt clinical and sonographic detection of local recurrence is important since subjects with relapsing melanomas or nonme...
Pathological factors that influence and predict survival following pelvic exenteration (PE) for locally advanced (LARC) or locally recurrent rectal cancer (LRRC), especially LRRC, remain poorly unders...
A retrospective cohort study was performed for all patients undergoing a curative PE for LARC or LRRC between 2008 and 2021 at a tertiary referral UK specialist colorectal hospital. Cox regression ana...
388 patients were included in the analysis with 256 resections for LARC and 132 for LRRC. 62.4% of patients were male with a median age of 59 years (IQR 49-67). 247 (64%) partial pelvic exenterations ...
A positive resection margin and poorly differentiated tumours are significant negative prognostic markers for survival and recurrence in LARC. The results of this study support the need to look for al...
Using CODA, a technique for three-dimensional reconstruction of large tissues, Kiemen et al. report observation of a microscopic focus of pancreatic cancer found in the vasculature of grossly normal h...
The initial approach to the treatment of desmoid tumors has changed from surgical resection to watchful waiting. However, surgery is still sometimes considered for some patients, and it is likely that...
We sought to explore whether a combined molecular and clinical prognostic model for relapse in patients with desmoid tumors treated with surgery would allow us to identify patients who might do well w...
This was a retrospective, single-center study of 107 patients with desmoid tumors who were surgically treated between January 1980 and December 2015, with a median follow-up of 106 months (range 7 to ...
The multivariable analysis showed that S45F mutations (hazard ratio 5.25 [95% confidence interval 2.27 to 12.15]; p < 0.001) and tumor in the extremities (HR 3.15 [95% CI 1.35 to 7.33]; p = 0.008) wer...
CTNNB1 S45F mutations combined with other clinical variables are a potential prognostic biomarker associated with the risk of relapse in patients with desmoid tumors. The developed nomogram is simple ...
Level III, therapeutic study....
A first local recurrence is common after resection or radiotherapy for brain metastasis (BM). However, patients with BMs can develop multiple local recurrences over time. Published data on second loca...
Patients were identified from a database at Brigham and Women's Hospital in Boston. Hazard ratios and 95% confidence intervals for predictors of a second local recurrence were computed using a Cox pro...
Of 170 identified surgically treated first locally recurrent lesions, 74 (43.5%) progressed to second locally recurrent lesions at a median of 7 months after craniotomy. Subtotal resection of the firs...
A second local recurrence occurred after 43.5% of craniotomies for first recurrent lesions. Subtotal resection and infratentorial location were the strongest risk factors for worse second local recurr...
The current study was undertaken to provide more detailed prognostic models for early prediction of local recurrences and local recurrence free survival (RFS) using different radiologic and pathologic...
One hundred patients with locally advanced rectal carcinomas decided to receive neoadjuvant CRT were retrospectively recruited, Hazard ratios (HR) were determined in the two cox regression models and ...
HR of 1st group of models: T+N, T+N+G, T+N+G+S, T+N+G+S+PNI, and T+N+G+S+PNI+R were summated and categorized into scores, these scores were significantly correlated with the risk of recurrence (Somer'...
We propose that the addition of biologic factors to staging of rectal cancer provide precise stratification and association with local recurrences in patients received preoperative CRT....
This study aims to identify prognostic factors and define the best extent of surgery for optimizing treatment of local recurrence (LR) following colorectal cancer (CRC)....
An institutional database of consecutive patients who underwent radical resection (R0/R1) of LR following CRC was analyzed prospectively from 2010 to 2021 at one tertiary cancer center....
In this study, 75 patients were included with LR following CRC and analyzed. Patients were categorized as compartmental resections (CompRe) (n = 47) if all adjacent organs were systematically removed,...
Complete compartmental surgery is safe and improves local control. Optimal LR resection needs to remove all contiguous organs, with or without tumor involvement....
RET-fused mesenchymal neoplasms mostly affect the soft tissue of paediatric patients. Given their responsiveness to selective RET inhibitors, it remains critical to identify those extraordinary cases ...
Clinicopathological features were assessed and partner agnostic targeted next-generation sequencing on clinically validated platforms were performed. The patients were 18, 53, and 55 years old and inc...
Our study expands the clinicopathological and genetic spectrum of mesenchymal neoplasms associated with RET fusions....
